TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02573194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfasts varying in protein source content on appetite
Description: In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfasts varying in protein source content on appetite
Description: In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
Study: NCT04088006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection of STYLAGE® HydroMax
Description: STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject.
Study: NCT03864939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dHAM
Description: A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No dHAM
Description: A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
Study: NCT01871350

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily intake for 10 weeks (+/- 2 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily intake for 10 weeks (+/- 2 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily intake for 10 weeks (+/- 2 weeks)
Study: NCT02774967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root coverage
Description: Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root coverage
Description: Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
Study: NCT01835418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: crossover comparison of amlodipine vs lisinopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: crossover comparison of amlodipine vs lisinopril
Study: NCT01959477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study: NCT00994682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone study drug
Description: 30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone Open Label
Description: Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone Open Label
Description: Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
Study: NCT02859324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01052129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium
Description: Naproxen Sodium Tablets 550 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Description: Naproxen Sodium Tablets 550 mg
Study: NCT04598568

Intervention type: DEVICE
Intervention: balanSys UNI
Description: Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
Study: NCT03653325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORI measurement
Description: Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen saturation measurement
Description: Oxygen (FiO2) will be titrated according to oxygen saturation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen saturation measurement
Description: Oxygen (FiO2) will be titrated according to oxygen saturation
Study: NCT01049217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin 75 mg-300mg twice daily during the course of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
Study: NCT03546764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous catheter
Description: tube inserted to drain hemothorax

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter
Description: tube inserted to drain hemothorax
Study: NCT00531700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health messaging
Description: Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health messaging
Description: Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health messaging
Description: Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health messages
Description: community level health messages unrelated to the study originating exposures
Study: NCT02923492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafERteens
Description: A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafERteens
Description: A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
Study: NCT04011943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation
Study: NCT01193426

Intervention type: OTHER
Intervention: Ascite liquid puncture
Description: Ascitic fluid obtained by paracentesis
Study: NCT03494478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-questionnaires on emotional topics
Description: The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
Study: NCT00903682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine (ETR, TMC125)
Description: 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz (EFV)
Description: 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
Study: NCT03169101

Intervention type: DRUG
Intervention: Nicotine patch
Description: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.

Intervention type: DRUG
Intervention: Nicotine patch
Description: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.

Intervention type: DRUG
Intervention: Nicotine patch
Description: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.

Intervention type: DRUG
Intervention: Nicotine patch
Description: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.

Intervention type: BEHAVIORAL
Intervention: Behavioral counseling
Description: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).

Intervention type: BEHAVIORAL
Intervention: Behavioral counseling
Description: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).

Intervention type: BEHAVIORAL
Intervention: Behavioral counseling
Description: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).

Intervention type: BEHAVIORAL
Intervention: Behavioral counseling
Description: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
Study: NCT03143946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin supplement;
Description: Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet advice
Study: NCT04488718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EnergieShake® Junior Powder Complete
Description: Oral Nutritional Supplement
Study: NCT01204398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan+amlodipine fixed dose combination
Description: after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
Study: NCT03443050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable
Description: This group will train over unstable surfaces to enhance balance abilities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable
Description: This group will train over stable surface to enhance balance abilities
Study: NCT01375088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propolis
Description: 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propolis
Description: 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
Study: NCT04351568

Intervention type: OTHER
Intervention: quesionnair
Description: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality

Intervention type: OTHER
Intervention: quesionnair
Description: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality
Study: NCT01843894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RU-101
Description: Recombinant human serum albumin

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RU-101
Description: Recombinant human serum albumin
Study: NCT03671694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium-YAG laser vaginal treatment
Description: Erbium-YAG laser vaginal treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erbium-YAG laser vaginal treatment
Description: Erbium-YAG laser vaginal treatment
Study: NCT01028027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol and tobramycin
Description: Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin and dexamethasone
Description: Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
Study: NCT02807103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 g intravenous pulse at day1 and day15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 g intravenous pulse at day1 and day15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-rituximab
Description: intravenous pulses at day1 and day15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-cyclophosphamide
Description: intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
Study: NCT04034446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: 0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
Study: NCT02811952

Intervention type: OTHER
Intervention: without intervention
Description: without intervention

Intervention type: OTHER
Intervention: without intervention
Description: without intervention
Study: NCT02112747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
Study: NCT01027182

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Raltegravir
Description: One 400mg tablet on day 1.
Study: NCT01614431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine to cystinosis patients with CKD stages 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine for cystinosis patients CKD stages 1 to 4
Study: NCT03576170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy
Description: aromatherapy by inhalation and/or therapeutic massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy
Description: aromatherapy by inhalation and/or therapeutic massage
Study: NCT02593266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Intervention Program (PIP) for depression
Description: Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~* Module 1: Depression and family~* Module 2: Psychoeducation about depression~* Module 3:The child's perspective on their parent's depression~* Module 4: Skills development~* Module 5: Preparation for the family session~* Module 6: Family session~* Module 7: Revision and future planning~* Follow-up
Study: NCT02534987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCPR2
Description: clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
Study: NCT01518933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin (Legalon-SIL)
Description: 20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT03383315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: One dose of intravenous tramadol 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: One dose of intravenous tramadol 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: One dose of intravenous metoclopramide 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9%
Study: NCT03681847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: normal saline 0.9% 15 ml/kg over 15-20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch
Description: hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: hypertonic saline 3% (7ml/kg) over 15-20 minutes.
Study: NCT03973281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Materna Prep Device
Description: Materna Prep Device

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC)
Study: NCT03503461

Intervention type: OTHER
Intervention: exosomes analysis
Description: Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.

Intervention type: OTHER
Intervention: exosomes analysis
Description: Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
Study: NCT02279394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Oral; Days 1-21 days Cycles 1-24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Oral; Days 1-21 days Cycles 1-24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
Study: NCT05717101

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT00979134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Patients start at a dose of 80 mg twice daily, with no washout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Single dose is followed by washout 5-10 days before multiple dose
Study: NCT04007341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
Study: NCT03218540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management protocol
Description: SVV protocol: keep SVV 10-13% and give fluid when SVV \> 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid management protocol
Description: SVV protocol: keep SVV 10-13% and give fluid when SVV \> 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg